EGFR and non-small cell lung carcinoma: For example, as discussed earlier, mutation in EGFR accounts for 10–30%, KRAS for 15–30%, and FGFR1 for 20% of NSCLC and targeted therapies against specific mutations has proven clinically more beneficial to patients compared to the cytotoxic chemotherapies [4].